Abstract from AroCell accepted for poster presentation during AACR 2019

An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study compares AroCell TK210 ELISA with TK-Liaison assay.

The study entitled "The Assay of Thymidine Kinase 1 in Sera from Subjects with Hematological and Solid Tumors with AroCell TK 210 ELISA: Comparison with TK-Liaison Assay and its Clinical Implications” by Jagarlamudi KK et al. shows that the AroCell TK 210 ELISA has a higher sensitivity for TK1 in sera from subjects with solid tumors and a similar sensitivity and specificity to the TK-­Liaison assay for hematological malignancies. This indicates that the AroCell TK210 ELISA may facilitate the application of TK1 as a biomarker for solid tumors. Furthermore, the robustness and convenience of the ELISA not only overcomes the limitations of TK-Liaison but also widens the clinical applications of TK1 in cancer management.

The study included a large group of serum samples (N=273; blood donors (N=102), hematological tumors (N=51), breast cancer (N=60) and urological conditions (N=60)) analyzed for TK1 protein by TK 210 ELISA and TK1 activity by TK-Liaison assay.

The full abstract is available following the link below. https://www.abstractsonline.com/pp8/#!/6812/presentation/5087

For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Michael Brobjer, February 28, 2019 at 10.30.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com

Attachment

• PM AACR abstract 20190228 EN